Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Wolfe Research Downgrades Silk Road Medical to Peer Perform

Wolfe Research analyst Mike Polark downgrades Silk Road Medical (NASDAQ:SILK) from Outperform to Peer Perform.

byBenzinga Newsdesk

February 7, 2023

1 minute read

Wolfe Research analyst Mike Polark downgrades Silk Road Medical (NASDAQ:SILK) from Outperform to Peer Perform.

Cowen & Co. Maintains Outperform on Core Scientific, Lowers Price Target to $3.75

By Benzinga Newsdesk

Today, 11:03 PM

Cowen & Co. analyst Stephen Glagola maintains Core Scientific (NASDAQ:CORZ) with a Outperform and lowers the price target from $4 to $3.75.

CORZ

Small Cap Consumer Research Maintains Buy on Betterware de Mexico SAB, Lowers Price Target to $30

By Benzinga Newsdesk

Today, 11:03 PM

Small Cap Consumer Research analyst Eric Beder maintains Betterware de Mexico SAB (NASDAQ:BWMX) with a Buy and lowers the price target from $45 to $30.

BWMX

SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $50

By Benzinga Newsdesk

Today, 11:03 PM

SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $54 to $50.

RCKT

SVB Leerink Maintains Market Perform on Immunogen, Lowers Price Target to $5

By Benzinga Newsdesk

Today, 11:03 PM

SVB Leerink analyst Jonathan Chang maintains Immunogen (NASDAQ:IMGN) with a Market Perform and lowers the price target from $6 to $5.

IMGN

Wolfe Research Downgrades Silk Road Medical to Peer Perform

Related Posts

Cowen & Co. Maintains Outperform on Core Scientific, Lowers Price Target to $3.75

Small Cap Consumer Research Maintains Buy on Betterware de Mexico SAB, Lowers Price Target to $30

SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $50

SVB Leerink Maintains Market Perform on Immunogen, Lowers Price Target to $5